Boardroom Alpha
10-Q primary document
MO · Quarterly Report (Form 10-Q) · Filed October 30, 2025

Altria Group Inc10-Q exhibit

exhibit992q32025-quarter.htm
Document

Exhibit 99.2


TRIAL SCHEDULE FOR CERTAIN CASES

Below is a schedule, as of October 27, 2025, setting forth by month the number of individual smoking and health cases against Philip Morris USA Inc. that are scheduled for but not in trial through December 31, 2025.

2025

Engle progeny                        
October 0
November 0
December 0

As of October 27, 2025, there are no Engle progeny cases in trial.

Other Individual Smoking & Health
October 1
November 0
December 0

As of October 27, 2025, there are no non-Engle progeny cases in trial.





Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer